CPAP may improve BMD among male patients with sleep apnea
Obstructive sleep apnea (OSA) and low bone mineral density (BMD) are two prevalent conditions with a significant negative impact on patients' well-being and quality of life.
Obstructive sleep apnea (OSA) treatment restores bone health. Support continuous positive airway pressure (CPAP) treatment improves bone mineral density (BMD) in male patients with severe OSA, according to a new study published in Journal of Clinical Sleep Medicine study.
Obstructive sleep apnea (OSA) and low BMD negatively impact patients' well-being and quality of life. Based on the data and results obtained from recent research, studies have consistently shown low BMD at different bone sites in male patients with a history of Obstructive sleep apnea (OSA).
CPAP treatment's efficacy for Obstructive sleep apnea (OSA) is demonstrated widely. More data on the evidence needs to be collected to understand its impact on bone mineral density (BMD) and other bone-related outcomes.
In the present study, researchers investigated the effect of twelve months of CPAP treatment on lumbar and femur bone mineral density (BMD) and bone-related serum biomarkers in male patients with severe OSA.
The study had Sixty patients with a mean age of 55 years. These patients underwent BMD measurement with dual-energy x-ray absorptiometry at baseline and after 12 months of CPAP treatment. The team examined levels of Vitamin D, parathyroid hormone (PTH), and calcium serum levels at the same time points.
The key results of the study are:
- There was a significant increase in BMD in the L1 and L2 vertebrae after CPAP treatment, along with increased vitamin D and calcium levels.
- There was a decrease in PTH levels.
- There was a significant correlation between increased BMD in L1 and decreased PTH serum levels.
They said that beneficial OSA treatment restores bone health and supports CPAP treatment as a feasible strategy to improve BMD in male patients with severe Obstructive sleep apnea (OSA).
They note that diagnosing and targeting OSA may be warranted in managing male patients with undetermined osteopenia and osteoporosis.
Further reading:
https://www.unboundmedicine.com/medline/citation/37677073/full_citation
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.